List view / Grid view

Sheraz Gul

 

Sheraz Gul

Head of Drug Discovery at the Fraunhofer Institute for Molecular…

22 June 2017 | By

Head of Drug Discovery at the Fraunhofer Institute for Molecular Biology and Applied Ecology

Proteases: How naturally occurring inhibitors can facilitate small molecule drug discovery for cysteine proteases

Cysteine proteases are expressed ubiquitously in the animal and plant…

20 August 2013 | By Sheraz Gul, Vice President and Head of Biology, European ScreeningPort GmbH

Cysteine proteases are expressed ubiquitously in the animal and plant kingdom and are thought to play key roles in maintaining homeostasis. The aberrant function of cysteine proteases in humans are known to lead to a variety of epidermal disease states such as inflammatory skin disease1. In marked contrast, the serine…

Screening In-Depth Focus 2013

In this Screening In-Depth Focus: New approaches to cell based…

30 July 2013 | By

In this Screening In-Depth Focus: New approaches to cell based assays for high content screening and analysis; Reduce, reuse, recycle: how drug repositioning is finding its niche in drug discovery; Workshop Review: Biochemical assays for screening. Screening roundtable...

The evolution of the Contract Research Organisation and the future of the pharmaceutical industry

This article discusses how the pharmaceutical industry can leverage its…

20 February 2013 | By , ,

This article discusses how the pharmaceutical industry can leverage its competencies in outsourcing to accelerate time to market, improve quality and increase innovation at all stages of the drug discovery and development process. The pharmaceutical industry is being battered by a perfect storm of not just one but three major…

Drug discovery assays for the histone deacetylase class of enzymes

The histone deacetylase (HDAC) class of enzyme are a group…

18 December 2012 | By Sheraz Gul and Gesa Witt, European ScreeningPort GmbH

The histone deacetylase (HDAC) class of enzyme are a group of conserved enzymes known for their ability to remove acetyl groups from lysine residues on histone tails. Since aberrant HDAC enzyme expression is observed in various diseases, there is increasing interest in finding small molecules which function as HDAC enzyme…

Discovery and validation of biomarkers for multiple sclerosis

Multiple Sclerosis (MS) is an autoimmune disease leading to a…

13 December 2011 | By Ole Pless and Sheraz Gul, European ScreeningPort GmbH

Multiple Sclerosis (MS) is an autoimmune disease leading to a chronic inflammation and degeneration of the central nervous system. It is one of the major neurological diseases with approximately 2.5 million suffering patients worldwide. Until now, the underlying mechanisms have not been fully elucidated, but the cause of the disease…

Implementing electronic laboratory notebooks to improve the efficiency of pre-clinical drug discovery

The pre-clinical phase of drug discovery spans a period in…

13 December 2011 | By Sheraz Gul, Vice President and Head of Biology, European ScreeningPort GmbH

The pre-clinical phase of drug discovery spans a period in the region of five years and requires contributions from multi-disciplinary teams often working at different sites. These teams can generate significant amounts of data which are processed using standard as well as specialist software. The recording of a substantial amount…

Reducing attrition in drug discovery: The role of biomarkers

The development of most diseases is often attributed to the…

20 June 2011 | By Sheraz Gul, Vice President & Head of Biology, European ScreeningPort GmbH

The development of most diseases is often attributed to the dysfunction of the activities of key proteins involved in biological processes and their modulation by a therapeutic agent is considered to offer the potential to alleviate the disease state.

Establishing assays and small molecule screening facilities for Drug discovery programs

Although many of the marketed small molecule drugs have been…

16 February 2011 | By Sheraz Gul, Vice President & Head of Biology, European ScreeningPort GmbH

Although many of the marketed small molecule drugs have been discovered by research and development efforts within the pharmaceutical industry, there has been a paradigm shift with external sources increasingly being relied upon to fill their pipelines. This trend is likely to increase and the key pre-clinical activities carried out…

Implementation of appropriate assays and HTS technologies in drug discovery

In this article, an overview regarding advances in assay formats…

9 May 2010 | By Sheraz Gul, Vice President, European ScreeningPort GmbH

In this article, an overview regarding advances in assay formats for specific target classes and options that should be considered when considering hardware will be given. There has been a significant growth in the assay and automation technologies that are available for compound screening activities and it is essential to…

The changing landscape of automation in pre-clinical drug discovery

Over the past decade we have seen a significant realignment…

22 February 2010 | By

Over the past decade we have seen a significant realignment of activities associated with drug discovery and this will continue for a multitude of reasons. Within the pharmaceutical industry we have seen significant changes e.g. a decrease in the numbers of drugs that are being approved by the regulatory authorities…

Lab Automation Roundtable

Participants: Dr Gordon R Alton, President and CEO, Altonyx Consulting…

12 December 2009 | By

Participants: Dr Gordon R Alton, President and CEO, Altonyx Consulting / Dr Scott Bowes Scientist, Novartis / Dr Sheraz Gul, Vice President and Head of Biology, European ScreeningPort / Chris Molloy, Vice President of Corporate Development, IDBS

Development and implementation of an automated compound screening activities facility

There has been a continuous move by the large commercially…

20 March 2009 | By

There has been a continuous move by the large commercially orientated players involved in Drug Discovery to initiate novel methods to increase income streams and productivity. An example of the former has been the acquisition of companies and their drug pipelines and in the case of the latter, rationalisation of…

The role of liquid handling technologies in successfully executing screening campaigns

High Throughput Screening (HTS) has for many years now been…

3 December 2008 | By

High Throughput Screening (HTS) has for many years now been playing a central role in drug discovery efforts to aid the identification of small molecule chemical entities that are capable of modifying the activity of disease relevant targets1. In order to make HTS a viable option to provide appropriate starting…